|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-5-24
|
|
pubmed:abstractText |
Gender-related aspects in chronic myeloid leukemia (CML) have not been studied well. We therefore analyzed 856 patients with Ph/BCR-ABL-positive CML from the German randomized CML-studies I (interferon alpha (IFN) vs hydroxyurea (HU) vs busulfan) and II (IFN+HU vs HU alone). The median observation time was 8.6 years. A total of 503 patients (59%) were male. Female patients were older (51 vs 46 years; P<0.0001), presented with lower hemoglobin (11.7 vs 12.5 g/dl; P<0.0001), higher platelet counts (459 vs 355 x 10(9)/l; P<0.0001), smaller spleen size (3 vs 4 cm below costal margin; P=0.0097), a lower rate of additional cytogenetic aberrations (9 vs 15%; P=0.018) and a less favorable risk profile (P=0.036). The transplantation rate was 14% for female (n=48) and 22% for male patients (n=113). Median survival was longer in female patients (58 vs 49 months; P=0.035) mainly attributable to better survival in the low- and intermediate-risk groups and, independent from risk groups, in the HU group. These results were confirmed by matched-pair analyses based on German population data (n=496, 59 vs 45 months; P=0.0006). This is the first analysis of gender aspects in CML using randomized trials. It demonstrates the relevance of analyses of gender differences in CML and in malignant disease at large.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
pubmed-author:BergerUU,
pubmed-author:German CML-Study Group,
pubmed-author:HasfordJJ,
pubmed-author:HehlmannRR,
pubmed-author:HeimpelHH,
pubmed-author:HochhausAA,
pubmed-author:HossfeldD KDK,
pubmed-author:KolbH-JHJ,
pubmed-author:LöfflerHH,
pubmed-author:LahayeTT,
pubmed-author:MaywaldOO,
pubmed-author:PfirrmannMM,
pubmed-author:PralleHH,
pubmed-author:QueisserWW,
pubmed-author:ReiterAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
984-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15830009-Adult,
pubmed-meshheading:15830009-Age Distribution,
pubmed-meshheading:15830009-Aged,
pubmed-meshheading:15830009-Antineoplastic Agents,
pubmed-meshheading:15830009-Antineoplastic Agents, Alkylating,
pubmed-meshheading:15830009-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15830009-Busulfan,
pubmed-meshheading:15830009-Cause of Death,
pubmed-meshheading:15830009-Female,
pubmed-meshheading:15830009-Humans,
pubmed-meshheading:15830009-Hydroxyurea,
pubmed-meshheading:15830009-Interferon-alpha,
pubmed-meshheading:15830009-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:15830009-Male,
pubmed-meshheading:15830009-Middle Aged,
pubmed-meshheading:15830009-Risk Factors,
pubmed-meshheading:15830009-Sex Characteristics,
pubmed-meshheading:15830009-Sex Distribution,
pubmed-meshheading:15830009-Survival Analysis,
pubmed-meshheading:15830009-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
|
|
pubmed:affiliation |
III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, 68305 Mannheim, Germany. ute.bergen@med3.ma.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
